FDA warns of vision loss risk linked to popular GLP-1 drugs like Wegovy, Zepbound

Executive Briefing

According to reporting by CNBC International Markets, The agency has found evidence of a potential increased risk of a rare eye condition linked to the use of GLP-1 drugs used for weight management and diabetes.

Detailed Factual Report

The U.S. Food and Drug Administration is requiring new safety warnings on all GLP-1 drugs after finding evidence of a potential increased risk of a rare eye condition, the agency said on Monday.

The condition, which can cause sudden vision loss, known as nonarteritic anterior ischemic optic neuropathy (NAION), is rare, and a causal relationship has not been established.

The FDA is requiring the makers of all GLP-1 medications to add a warning about the potential increased risk of NAION associated with use of these medications, it said.

NAION is a condition that can result in sudden decreased vision, including permanent vision loss. It is caused by decreased blood flow to the front part of the ​optic nerve — the underlying cause is not completely understood, however.

Verified Data Points & Key Takeaways

Geographic Scope & Community Impact

Recommended Action & Safety Guidelines

Source & Verification Provenance

Information in this article was compiled directly from records provided by CNBC International Markets. Access the primary source document at: https://www.cnbc.com/2026/11/10/fda-warning-vision-loss-glp1-wegovy-zepbound.html. Reporting and editorial review conducted by the USA NOW News Desk.